argenx up by a third on CIDP data

Belgo-Dutch autoimmune diseases specialist argenx (Nasdaq: ARGX) has announced positive top-line results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in chronic inflammatory demyelinating polyneuropathy (CIDP).

The study met its primary endpoint, demonstrating a 61% lower risk of relapse with Vyvgart Hytrulo compared to placebo, which was statistically significant.

"We may have a novel weapon to combat this debilitating condition"Some 67% of assessed patients demonstrated evidence of clinical improvement, indicating that IgG autoantibodies play a significant role in the underlying biology of CIDP.